Loading...
Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
Immune checkpoint inhibition has been approved for front-line treatment of metastatic bladder cancer in patients who are cisplatin-ineligible and demonstrate programmed death-ligand 1 (PD-L1) positivity. This approval followed the positive results of IMvigor210 and KEYNOTE-052 studies. Immunotherapy...
Na minha lista:
| Udgivet i: | Ther Adv Urol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8053833/ https://ncbi.nlm.nih.gov/pubmed/33948120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562872211004797 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|